GeoVax Announces 1-for-24 Reverse Stock Split to Regain Compliance With Nasdaq Minimum Bid Requirement
GeoVax Labs announced a 1-for-24 reverse stock split to meet Nasdaq's minimum bid price requirement of $1.00 per share. The company aims to regain compliance and avoid delisting. GeoVax is a biotech firm focused on immuno-oncology and preventive vaccines.
How this was made

The 30-second read
Why it matters
The split aims to lift the share price above $1, preserving Nasdaq listing and potentially improving liquidity.
Market read
A compliance‑driven reverse split is a corporate action that can affect price perception and liquidity for micro‑cap stocks.
What to watch
Potential upcoming clinical data releases could offset negative sentiment from the split.
Background
GeoVax Labs (GOVX) is a clinical‑stage biotech trading below Nasdaq's $1 minimum bid price, prompting the reverse split.
Ticker impact
GeoVax announced a 1-for-24 reverse stock split to meet Nasdaq's minimum bid price requirement.
potential downward pressure as the market prices in the dilution of share count and compliance concerns
Reverse splits on low‑price microcaps often trigger sell‑offs, especially when driven by exchange compliance.
Market effects
May signal compliance pressure on other low‑price biotech stocks.
Limited to U.S. small‑cap biotech segment.
Minimal global impact.
Counterpoint
Some investors may view the split as a catalyst for a short‑term rally if the compliance fix restores Nasdaq listing.
Key entities
- companyGeoVax Labs, Inc.
Biotech firm conducting immuno‑oncology and vaccine trials.

